HRSA to Enforce 340B Program Oversight of Drug Manufacturers Next Year and Share 340B Ceiling Prices with Covered Entities
Two announcements could have broader implications.
The Health Resources and Services Administration published two announcements in late 2018. The focal point of these announcements surrounds the agency’s plans to heighten oversight of drug manufacturers under the 340B drug pricing program, as well as clarity for the 340B ceiling prices for covered entities. This white paper outlines the HRSA's these announcements and their implications for covered entities.
Sign up for a free Bronze membership today to receive your complimentary white paper!
Please provide a valid business e-mail to receive your access instructions.
Already a member? Log In
You will receive a Free Bronze Membership
to HR Resource with your White Paper!